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INTRODUCTION
The relationship between breast cancer and obesity has been 
recognized for many years [1,2]. The postulated mechanisms 
for the increased risk of breast cancer in obese women are ele-
vated estrogen levels and insulin resistance and the influence of 
insulin-like growth factor (IGF) in the pathogenesis of breast 
cancer [3,4]. Multiple studies have indicated that some adipose 
tissue-derived hormones called adipocytokines, such as leptin 
and adiponectin, may significantly influence the growth and 
proliferation of tumors [5-7]. 
Leptin, a product of the obese (Ob) gene, is produced predom-
inantly in adipose tissue and expressed in normal mammary 
epithelial cells and malignant breast tissues [8-10]. Some inves-
tigators have reported that expression of leptin and leptin recep-
tor (ObR) is significantly higher in breast carcinoma compared 
to normal mammary tissue [11,12]. Leptin is involved in a var- 
iety of functions including appetite regulation, bone forma-
tion, reproduction, and angiogenesis [13]. Several studies have 
investigated the effects of leptin on breast cancer, and suggest 
that leptin may affect processes related to cancer initiation and 
progression, resulting in metastatic development [9,11,14,15].
Leptin acts through its receptor (ObR), which is encoded 
by the Ob gene. In human tissues, four different ObR variants 
have been described but only the long ObR isoform (ObR1) 
has full signaling potential [16]. Binding of leptin to ObR acti-
vates the Janus kinase/signal transducer and activator of tran-
scription (JAK/STAT) signaling pathway, and induction of JAK 
stimulates phosphoinositol-3-kinase (PI3Kinase). Activation 
of PI3Kinase can increase cell migration and invasion via the 
Rac/Rho pathways, and stimulate the major growth and sur-
vival Akt pathway [7].
Adiponectin is another adipocytokine predominantly secret-
ed by adipocytes [6]. In contrast to other adipocytokines, adi-
ponectin levels are inversely correlated with central fat accu-
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Purpose: Adipocytokines, such as leptin, resistin, and adiponec-
tin, are associated with obesity and breast cancer. Several studies 
have indicated that adipocytokines may influence tumor growth 
or differentiation. The aims of this study were to determine the 
expression of leptin, leptin receptor (ObR), adiponectin and adi-
ponectin receptor (AdipoR) in human breast cancer, to evaluate 
their prognostic significance in the breast cancer. Methods: Speci-
mens from 198 patients with primary breast cancer were enrolled, 
and representative paraffin tumor blocks were selected for con-
structing tissue microarrarys (TMA). Immunohistochemical stain-
ing for leptin, ObR, adiponectin, and AdipoR was performed us-
ing TMA, and the clinicopathologic characteristics were evaluated 
from the patient’s medical records. Results: Stage 0 breast can-
cer accounted for 41 cases, and 157 cases were invasive can-
cer. Positive rates of leptin and ObR expression in the ductal car-
cinoma in situ (DCIS) group were significantly higher than those 
of the invasive cancer group (97.4% vs. 34.0%, p<0.001; 74.4% 
vs. 29.8%, p<0.001). However, positive rates of adiponectin and 
AdipoR expression in the invasive cancer group were significantly 
higher than those in the DCIS group (53.7% vs. 33.3%, p=0.024; 
59.9% vs. 26.3%, p<0.001). High leptin expression was signifi-
cantly associated with high Ki-67 expression (p=0.016). High adi- 
ponectin expression was significantly correlated with smaller tu-
mor size (p=0.001). Conclusion: We suggest that losses of leptin 
and ObR expression could be associated with invasive cancer, 
whereas high adiponectin and AdipoR expression may be asso-
ciated with breast cancer invasiveness.
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mulation [17], and an inverse correlation was found between 
plasma adiponectin levels and the histological grade of breast 
cancer [18,19]. However, the precise effects of adiponectin in 
breast cancer are still unclear. 
Two types of adiponectin receptors (AdipoR1 and R2) have 
been described, and adiponectin acts via those receptors. Adi-
poR1 acts mainly through adenosine monophosphate-activat-
ed protein kinase (AMPK) pathways, whereas AdipoR2 is more 
closely linked to the activation of the peroxisome proliferator-
activated receptor alpha pathway. The growth inhibitory effect 
of adiponectin is influenced mainly through AMPK activation, 
while anti-cancer effects of adiponectin are mainly achieved 
by activation of AdipoR1 [20,21]. 
Leptin stimulates the invasion of breast cancer cells [11,14, 
22]. However, the relationship between leptin, ObR, adiponec-
tin, AdipoR, and breast cancer invasiveness has not been in-
vestigated in human tissue. In the present study, we monitored 
the expression of leptin, ObR, adiponectin and AdipoR in breast 
cancer specimens using immunohistochemistry and analyzed 
how changes in expression correspond to clinicopathological 
parameters including breast cancer invasiveness. 
METHODS
Patients and materials 
A total of 198 patients with primary breast cancer who un-
derwent surgery between January 2003 and April 2008 at Dae-
gu Catholic University Medical Center were included. All re-
sected specimens were stained with hematoxylin and eosin 
(H&E) and histologically examined. According to the pathol- 
ogic diagnosis, 41 patients had ductal carcinoma in situ (DCIS), 
and 157 patients had invasive breast cancer. 
The clinicopathological characteristics such as menopausal 
state, body mass index (BMI), and tumor invasiveness were 
evaluated based on pathological reports and medical records. 
Prognostic factors including tumor size, nodal status, distant 
metastasis, histological grade, lymphovascular invasion, and 
estrogen receptor (ER), progesterone receptor (PR), human epi-
dermal growth factor receptor-2 (HER2), Bcl-2, Ki67, and p53 
expression were evaluated in invasive breast cancer. Lesion stag-
ing was assessed according to the sixth edition of the Ameri-
can Joint Committee on Cancer (AJCC) staging manual for 
breast cancer.
Construction of tissue microarrays (TMA)
Representative paraffin tumor blocks were selected accord-
ing to the primary evaluation of H&E-stained slides before they 
were prepared for TMA. Two tumor tissue cores (1 mm in di-
ameter) were taken from each of the donor breast cancer tissue 
blocks with a manual punch arrayer (Quick-Ray
TM; Uni-Tech 
Science, Seoul, Korea). The cores were placed in a new recipi-
ent paraffin block that ultimately contained 72-96 tissue cores. 
Each array block contained both tumor and control tissue sam-
ples. Multiple sections (5-μm in thickness) were cut from the 
TMA blocks and then mounted onto microscope slides. The 
TMA H&E-stained sections were reviewed under light micros-
copy to confirm the presence of representative tumor areas. 
Immunohistochemical staining
Immunohistochemistry was conducted on 5 μm-thick TMA 
tissue sections using the Bond Polymer Intense Detection Sys-
tem (Leica Microsystems, Victoria, Australia) according to the 
Table 1. General patient characteristics (n=198)
Variables No. (%)
Age (yr)* 50.87 (25-81)
Sex
   Female
   Male
 
197 (99.5)
  1 (0.5)
Menopausal state
   Premenopausal
   Postmenopausal
 
103 (52.3)
  94 (47.7)
BMI (kg/m
2)
   ≥25
   <25
 
  69 (36.7)
119 (63.3)
Pathologic diagnosis
   DCIS
   Invasive cancer
  41 (20.7)
157 (79.3)
AJCC staging
   0
   I
   II
   III
   IV
 
  41 (20.7)
  57 (28.8)
  71 (35.9)
  26 (13.1)
  3 (1.5)
Axillary lymph node metastasis
   Negative
   Positive
 
123 (64.1)
  69 (35.9)
Distant metastasis
   Negative
   Positive
 
195 (98.5)
  3 (1.5)
Histologic grade
   1
   2
   3
 
  41 (20.7)
  67 (33.8)
  34 (17.2)
ER
   Negative
   Positive
 
  67 (34.9)
125 (65.1)
PR
   Negative
   Positive
 
  47 (24.5)
145 (75.5)
HER2 expression
   No overexpression
   Overexpression
 
123 (64.4)
  68 (35.6)
BMI=body mass index; DCIS=ductal carcinoma in situ; AJCC=American 
Joint Committee on Cancer; ER=estrogen receptor; PR=progesterone 
receptor. 
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manufacturer’s instruction with minor modifications. Briefly, 
the 5 μm-thick sections of formalin-fixed and paraffin-embed-
ded TMA tissues were deparaffinized with Bond Dewax Solu-
tion (Leica Microsystems), and an antigen retrieval procedure 
was performed using Bond ER Solution (Leica Microsystems) 
for 30 minutes at 100°C. The endogenous peroxidase was quen-
ched by a 5-minute incubation with hydrogen peroxide. Sec-
tions were incubated for 15 minutes at ambient temperature 
with a rabbit polyclonal anti-leptin antibody (ab16227, 1:150; 
Abcam, Cambridge, UK), a rabbit polyclonal anti-leptin recep-
tor antibody (ab60042, 1:150; Abcam), a mouse monoclonal 
anti-adiponectin antibody (ab22554, 1:150; Abcam) and a goat 
polyclonal anti-adiponectin receptor antibody (ab77611, 1:200; 
Abcam) using a biotin-free polymeric horseradish peroxidase-
linker antibody conjugate system in a Bond-Max automatic 
slide stainer (Leica Microsystems). Human adipocytes (leptin 
and adiponectin), heptocellular carcinoma (leptin receptor) 
and normal liver (adiponectin receptor) tissues were used as 
positive controls.
Interpretation of immunohistochemical stain
Leptin, ObR, adiponectin, and AdipoR expression levels were 
graded on a scale of 0 to 2 based on staining intensity and pro-
portion of positive tumor cells by an expert pathologist who was 
blinded to the patient’s clinical records. The staining was scored 
as 0 if no cancer cells were reactive, 1 if staining was weakly posi- 
tive in <2/3 of cancer cells, or strongly positive in <1/3 of can-
cer cells, and 2 if staining was weakly positive in >2/3 of can-
cer cells, or strongly positive in >1/3 of cancer cells. Immuno-
histochemical staining in breast cancer tissue was classified as 
negative (score 0) or positive (score 1 and 2). 
A cutoff value of 10% for the stained nuclei was used to de-
fine ER and PR positivity. Cytoplasmic staining with any inten-
sity in >10% of the tumor cells was scored as positive for Bcl-2. 
Membranous staining for HER2 with strong complete stain-
ing in 10% of the tumor cells was regarded as HER2 overex-
pression. The p53 staining was scored positive if >10% of the 
cells were stained with strong intensity. The Ki-67 labeling in-
dex was expressed as a percentage and was graded as “high” if 
the number of positive cells was ≥10%.
Statistical analysis 
The statistical analysis was performed using SPSS version 15.0 
(SPSS Inc., Chicago, USA). The relationship between leptin, 
ObR, adiponectin, AdipoR expression and clinicopathological 
features was assessed by the chi-square test. A p-value of less 
than 0.05 was considered statistically significant.
RESULTS
Clinicopathologic characteristics of the patients
The average age of the 198 patients with breast cancer was 
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Figure 1. Representative examples of immunohistochemical expression of leptin (A, E), leptin receptor (B, F), adiponectin (C, G), and adiponectin re-
ceptor (D, H) in invasive ductal carcinoma (upper row) and ductal carcinoma in situ (lower row). Staining for leptin, leptin receptor, adiponectin, and 
adiponectin receptor appears in the cytoplasm of tumor cells. We interpreted the results semi-quantitatively based on the number of stained cells and 
signal intensity (immunohistochemical staining, ×200). Scale bar means 200 micrometer.Expression of Adipocytokine and Their Receptors in Breast Cancer 99
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50.87±11.10 years (range, 25-81 years). Among 197 female pa-
tients, 95 (47.3%) were postmenopausal and 106 (52.7%) were 
premenopausal. The mean BMI was 24.1±3.4 kg/m
2. Accord-
ing to criteria of the World Health Organization, a BMI ≥25 
kg/m
2 is defined as overweight, a BMI between 18.5 kg/m
2 and 
24.9 kg/m
2 is normal, and a BMI <18.5 kg/m
2 is considered 
underweight. A total of 69 patients (36.7%) were overweight, 
and 119 patients (63.3%) were normal or underweight (Table 
1). TNM staging was as follows: 41 patients (20.7%) had stage 
0, 57 patients (28.8%) had stage I, 71 patients (35.9%) had stage 
II, 26 patients (13.1%) had stage III, and three (1.5%) patients 
had stage IV. The histological types of DCIS were comedo (n= 
16), solid (n=10), papillary (n=11), and cribriform (n=4), 
and those of invasive cancers were ductal carcinoma not oth-
erwise specified (n=154), lobular carcinoma (n=1), medul-
lary carcinoma (n=1), and metaplastic carcinoma (n=1).
Immunohistochemical findings of leptin, ObR, adiponectin, 
and AdipoR
We constructed two DCIS TMAs and four invasive breast 
cancer TMAs, which included specimens from 41 DCIS and 
157 invasive breast cancer cases. Some of the tissue specimens 
that were partly lost during TMA construction or were unavail-
able were excluded. Figure 1 shows representative micro- 
photograph of immunohistochemical expression of the adipo- 
cytokines and their receptors. Positive expression rates for 
leptin, ObR, adiponectin, and AdipoR were 47.1% (89/189), 
38.9% (74/190), 49.5% (93/188), and 53.2% (101/190), respec-
tively. 
Relationship between leptin, ObR, adiponectin, AdipoR 
expression and clinicopathological features in DCIS
As shown in Figure 2, positive rates of leptin and ObR expres-
sion in the DCIS group were significantly higher than those of 
Table 2. Clinicopathologic characteristics related to adipocytokines and their receptor expression in breast cancer tissues
Variables
Leptin ObR Adiponectin AdipoR
Positive rate 
(%) p-value
Positive rate 
(%) p-value
Positive rate 
(%) p-value
Positive rate 
(%) p-value
Menopausal state
   Premenopausal
   Postmenopausal
 
46.4
47.3
0.906  
37.4
41.1
0.599  
50.0
48.3
0.818  
56.1
49.5
0.359
BMI (kg/m
2)
   ≥25
   <25
 
44.8
49.1
0.572  
44.8
37.4
0.327  
43.9
54.4
0.177  
53.7
52.6
0.886
Pathologic diagnosis
   DCIS
   Invasive cancer
 
97.4
34.0
<0.001  
74.4
29.8
<0.001  
33.3
53.7
0.024  
26.3
59.9
<0.001
DCIS subtype
   Comedo (n=16)
   Cribriform (n=4)
   Papillary (n=11)
   Solid (n=10)
 
94.1
100.0
100.0
100.0
0.722  
70.6
100.0
55.6
88.9
0.244  
29.4
75.0
11.1
44.4
0.125  
31.3
33.3
0.0
40.0
0.216
IBC subtype
   IDC (NOS) (n=154)
   ILC (n=1)
   Medullary (n=1)
   Metaplastic (n=1)
 
34.0
0.0
100.0
0.0
0.396  
29.1
0.0
100.0
100.0
0.159  
53.4
100.0
0.0
100.0
0.409  
61.1
0.0
0.0
0.0
0.207
ObR=leptin receptor; AdipoR=adiponectin receptor; BMI=body mass index; DCIS=ductal carcinoma in situ; IBC=invasive breast cancer; IDC=invasive 
ductal carcinoma; NOS=not otherwise specified; ILC=invasive lobular cancer. 
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Figure 2. Comparison of leptin (A), leptin receptor (obR) (B), adiponectin 
(C), and adiponectin receptor (AdipoR) (D) expression levels between 
patients with ductal carcinoma in situ (DCIS) and invasive breast cancer. 
Expression of leptin and ObR were significantly higher in the DCIS group 
than in the invasive cancer group, and adiponectin and AdipoR expres-
sion was significantly higher in the invasive cancer group than the DCIS 
group.100   Young-Ju Jeong, et al.
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Table 3. Correlation between the expression of leptin, leptin receptor 
and prognostic factors in invasive breast cancer tissues
Variables
Leptin Leptin receptor
Positive 
rate (%) p-value
Positive 
rate (%) p-value
Tumor size (cm)
   ≤2
   >2
 
34.1
33.8
0.972  
34.5
23.9
0.155
Node metastasis
   Negative
   Positive
 
34.6
34.3
0.976  
36.3
23.2
0.083
Distant metastasis
   Negative
   Positive
 
34.0
33.0
0.980  
30.4
  0.0
0.254
EIC
   Negative
   Positive
 
38.0
26.7
0.257  
37.0
23.3
0.170
Histologic grade
   1 
   2
   3
 
20.0
40.9
28.1
0.071  
37.5
33.8
17.6
0.144
LVI
   Negative
   Positive
 
34.0
40.5
0.478  
35.0
24.3
0.235
ER
   Negative
   Positive
 
31.6
35.5
0.624  
21.1
35.1
0.067
PR
   Negative
   Positive
 
23.7
37.5
0.120  
23.7
31.9
0.341
HER2 expression
   No overexpression
   Overexpression
 
32.3
37.0
0.556  
27.8
33.3
0.479
Bcl-2 expression
   Negative
   Positive
 
35.1
32.9
0.773  
20.3
40.5
0.007
p53 expression
   Negative
   Positive
 
31.1
37.2
0.447  
26.2
33.3
0.355
Ki-67 expression (%)
   <10
   ≥10
 
27.8
54.5
0.016  
33.3
53.3
0.072
BMI (kg/m
2)
   <25
   ≥25
 
37.0
30.8
0.454  
26.9
38.5
0.148
EIC=extensive intraductal component; LVI=lymphovascular invasion; 
ER=estrogen receptor; PR=progesterone receptor; BMI=body mass 
index.
Table 4. Correlation between the expression of adiponectin, adiponec-
tin receptor and prognostic factors in invasive breast cancer tissues
Variables
Adiponectin Adiponectin receptor
Positive 
rate (%) p-value
Positive 
rate (%) p-value
Tumor size (cm)
   ≤2
   >2
 
65.5
38.5
0.001  
64.0
54.5
0.241
Node metastasis
   Negative
   Positive
 
56.3
50.7
0.505  
59.8
60.9
0.889
Distant metastasis
   Negative
   Positive
 
53.4
66.7
0.649  
60.0
50.0
0.774
EIC
   Negative
   Positive
 
59.3
48.3
0.295  
63.4
60.0
0.735
Histologic grade
   1
   2
   3
 
59.0
59.1
40.6
0.186  
65.0
60.6
55.9
0.726
LVI
   Negative
   Positive
 
54.5
52.8
0.855  
64.0
60.5
0.706
ER
   Negative
   Positive
 
51.8
54.8
0.717  
58.6
60.6
0.805
PR
   Negative
   Positive
 
52.6
54.1
0.879  
53.8
61.9
0.374
HER2 expression
   No overexpression
   Overexpression
 
49.0
62.3
0.119  
60.2
59.3
0.909
Bcl-2 expression
   Negative
   Positive
 
52.1
56.2
0.618  
61.3
58.7
0.739
p53 expression
   Negative
   Positive
 
48.3
59.3
0.190  
60.3
58.6
0.835
Ki-67 expression (%)
   <10
   ≥10
 
63.9
63.6
0.981  
34.7
65.3
0.029
BMI (kg/m
2)
   <25
   ≥25
 
58.7
47.1
0.181  
58.1
61.5
0.683
EIC=extensive intraductal component; LVI=lymphovascular invasion; 
ER=estrogen receptor; PR=progesterone receptor; BMI=body mass 
index.
the invasive cancer group (97.4% vs. 34.0%, p<0.001; 74.4% vs. 
29.8%, p<0.001), and positive rates of adiponectin and Adi-
poR expression in the invasive cancer group were significantly 
higher than those of the DCIS group (53.7% vs. 33.3%, p=0.024; 
59.9% vs. 26.3%, p<0.001). 
Comparing the expression of leptin, ObR, adiponectin, and 
AdipoR with menopausal status and BMI, no significant cor-
relation was observed and a comparison according to the his-
tological subtypes of DCIS and invasive breast cancer showed 
no significant differences in the expression levels of each of the 
adipocytokines and their receptors (Table 2). 
Correlation between the expression of leptin, ObR, 
adiponectin, and AdipoR and prognostic factors in invasive 
breast cancer tissues
We analyzed the correlation between leptin, ObR, adiponec-
tin, AdipoR expression and prognostic factors in invasive breast 
cancer. The results showed that leptin expression was signifi-Expression of Adipocytokine and Their Receptors in Breast Cancer 101
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cantly associated with high Ki-67 expression (p=0.016), and 
ObR expression was significantly associated with negative Bcl-2 
expression (p=0.007). However, neither leptin expression nor 
ObR expression was significantly correlated with menopausal 
state, BMI, distant metastases, histological grade, HER2 expres-
sion, or p53 expression (Table 3). 
Adiponectin expression was significantly associated with 
lower T-stage (p=0.028) in invasive breast cancer, but not with 
menopausal state, BMI, N stage, distant metastases, histologi-
cal grade, lymphovascular invasion, hormonal receptor status, 
HER2 expression, or the other immunohistochemical parame-
ters. AdipoR expression was significantly associated with high 
Ki-67 expression (p=0.029) in invasive breast cancer (Table 4).
Correlation between leptin and ObR expression and 
adiponectin and AdipoR expression 
Leptin expression was significantly associated with ObR ex-
pression (p<0.001), and adiponectin expression was signifi-
cantly associated with AdipoR expression (p<0.001). How- 
ever, leptin and adiponectin expression were not significantly 
correlated (p=0.463), and neither was ObR or AdipoR (p= 
0.175).
DISCUSSION
We observed that leptin, ObR, adiponectin, and AdipoR were 
significantly related to invasiveness of breast cancers. Positive 
rates of leptin and leptin receptor expression observed in the 
DCIS group were higher than those of the invasive cancer group, 
but positive rates of adiponectin and AdipoR expression were 
higher in the invasive cancer group. These results suggest that 
losses of leptin and ObR expression could be associated with 
breast cancer invasion. We assume that leptin and ObR expres-
sion is related to an early stage of carcinogenesis such as cancer 
development, while adiponectin and AdipoR may be associat-
ed with invasiveness of breast cancer. Our results also showed 
that leptin expression was significantly associated with a high 
Ki-67 labeling index, suggesting that leptin is associated with 
the proliferation of breast cancer cells, which is supported by 
recent studies [5-7,14].
Although some in vitro studies have demonstrated that leptin 
promotes invasiveness of human breast cancer cells, epidemi-
ological studies showing a relation between leptin expression 
and invasiveness of breast cancer have not been reported. Sax-
ena et al. [14] showed that bidirectional crosstalk between leptin 
and IGF-1 signaling promotes invasion and migration of breast 
cancer cells via transactivation of epidermal growth factor re-
ceptors. McMurtry et al. [22] showed that leptin increases the 
invasiveness and matrix metallopeptidase 2 activity of breast 
cancer cells, which are mediated by Jun N-terminal kinases 
activation. In contrast, our results revealed that leptin and ObR 
expression was inversely correlated with breast cancer invasive-
ness. Additionally, leptin and ObR expression was not associ-
ated with distant metastasis, histological grade, lymphovascu-
lar invasion, or the other immunohistochemical parameters. 
From these results, we suggest that leptin and ObR are related 
to tumorigenesis of breast cancer, but not invasiveness.
A number of studies were initiated to understand the mech-
anisms associated with leptin and mammary tumor develop-
ment [23,24]. Adipocytokines circulating in the blood exert 
their biological actions on target cells not only by classical en-
docrine mechanisms but also through paracrine or autocrine 
pathways [23-25]. Expression of leptin in breast cancer tissue is 
not representative of serum leptin concentrations, and is con-
sidered to be a product of the paracrine pathway [23]. Leptin 
mediates the estrogenic stimulation of tumor cells through a 
paracrine mechanism, and increases other factors that con-
tribute to cell proliferation and angiogenesis during mamma-
ry tumor growth [24]. Furthermore, the autoregulation of leptin 
augments its signal by stimulating expression of itself and its 
receptor which supports an autocrine function [25]. Our results 
showed that leptin expression was significantly associated with 
ObR expression, and that adiponectin expression was signifi-
cantly associated with AdipoR expression. Furthermore, leptin 
and adiponectin appear to have antagonistic effects in breast 
cancer invasion, although they were not significantly correlat-
ed. We suppose that leptin and adiponectin autoregulate their 
receptor through an autocrine pathway, and that leptin and adi- 
ponectin affect each other through a paracrine pathway.
The precise effects of adiponectin on breast cancer risk are 
still unclear. Epidemiological studies have reported a signifi-
cant inverse association between adiponectin and breast can-
cer risk [17,19], and several in vitro studies have demonstrated 
a growth inhibitory action of adiponectin on breast cancer cells 
[26,27]. In contrast, Karaduman et al. [28] reported that tissue 
adiponectin levels in patients with breast cancer were signifi-
cantly higher than healthy individuals, and that high tissue adi- 
ponectin levels were associated with a significantly increased 
risk for breast cancer compared with those with low tissue adi- 
ponectin levels. 
The relationship between adiponectin expression and breast 
cancer invasiveness is still unknown. Pfeiler et al. [29] report-
ed a positive correlation between lymphovascular and vascu-
lar invasion and AdipoR2 but not AdipoR1 expression. Jardé 
et al. [10] showed that adiponectin expression is higher in nor-
mal adjacent tissue than in neoplastic tissue, and that adiponec-
tin expression in invasive ductal carcinoma is higher than that 
of in situ ductal carcinoma. In our study, we found that adipo-102   Young-Ju Jeong, et al.
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nectin and AdipoR expression in invasive breast cancer was 
significantly higher than that of DCIS, suggesting that adipo-
nectin and AdipoR are related to breast cancer invasiveness. In 
this way, adiponectin may be associated with the progression 
and invasiveness of tumors and involved in later stages of breast 
cancer development. 
As obesity is a key factor associated with circulating adipo-
cytokine levels, obesity indices such as BMI may be related to 
adipocytokines and their receptor levels in tissues. However, 
in our immunostaining analysis, we did not find any associa-
tion between adipocytokine expression and BMI. This finding 
was consistent with the idea that peritumoral adipose tissues 
are a key contributor to circulating leptin levels and tumor leptin 
production and act as a minor source of blood adipocytokine 
[23]. Because BMI is the best proxy for body fat percentage 
among ratios of weight and height and is generally used as a 
vague means of estimating adiposity, BMI could be related to 
adipocytokine levels in blood but not in tissues. This assump-
tion is supported by the observation of Hancke et al. [30] who 
found a strong positive association between leptin levels and 
BMI. 
Our present study has several limitations. First, we could not 
evaluate adipocytokine expression in peritumoral normal breast 
tissue, because TMA was used. So, our results were limited to 
tumor tissues and a comparative study of the adipocytokine 
expression in breast cancer with a control group, including nor-
mal or benign breast tissue between cancer tissue, may be nec-
essary to understand adipocytokine effects. Second, we could 
not evaluate adipocytokine expression in breast cancer tissue 
and blood samples simultaneously. Although we assumed that 
the level of serum adipocytokine is not correlated with tissue 
adipocytokine expression based on multiple studies [17,19,23, 
28], analysis of serum adipocytokine may be necessary to form 
a solid conclusion. Third, the adipocytokine action mechanism 
in breast tissue was not studied, which can be further clarified 
through in vitro experiments. Despite these limitations, we be-
lieve that this study is meaningful because, it provided evidence 
that leptin is inversely related to cancer invasion, and that adi-
ponectin is significantly related to breast cancer invasion.
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